Table 1.

Comparisons of demographic and clinical characteristics between the patients with NMOSD, patients with MS and healthy controls.

	NMOSD (n = 14)	MSa (n = 12)	Controls (n = 10)	P
Median age, years (IQR)	54.0 (37.0–63.0)	55.5 (40.5–63.5)	44.5 (24–57)	0.416
Female, n (%)	10 (71)	7 (58)	7 (70)	0.769
Presence of serum Ab, n (%)	NMO-IgG/AQP4: 8 (57) MOG: 1 (7)	n/a	n/a
Median disease duration, years (IQR)	8 (3.0–11.0)	13 (7.5–20.5)	n/a
Receiving immunosuppressants or immunomodulatory agents, n (%)	14 (100)b	5 (42)c	n/a	.

Abbreviations: Ab, antibody; AQP4, aquaporin 4; IgG: immunoglobulin G; IQR, interquartile range; MOG, myelin oligodendrocyte glycoprotein; MS, multiple sclerosis; NMO, neuromyelitis optica; NMOSD, neuromyelitis optica spectrum disorders; n/a, not applicable or not available; SD, standard deviation.

^aEight (67%) MS patients had relapsing remitting MS, two (17%) had secondary progressive MS, and two (17%) had primary progressive MS.